Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis

David Aviezer; Dalit Hecht; Michal Safran; Magdalena Eisinger; Guido David; Avner Yayon

doi:10.1016/0092-8674(94)90031-0

Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis

David Aviezer, Dalit Hecht, Michal Safran, Magdalena Eisinger, Guido David, Avner Yayon

Research output: Contribution to journal › Article › peer-review

507 Scopus citations

Abstract

A survey of defined species of cell surface and extracellular matrix heparan sulfate proteoglycans (HSPG) was performed in a search for cellular proteoglycans that can promote bFGF receptor binding and biological activity. Of the various affinity-purified HSPGs tested, perlecan, the large basement membrane HSPG, is found to induce high affinity binding of bFGF both to cells deficient in HS and to soluble FGF receptors. Heparin-dependent mitogenic activity of bFGF is strongly augmented by perlecan. Monoclonal antibodies to perlecan extract the receptor binding promoting activity from active HSPG preparations. In a rabbit ear model for in vivo angiogenesis, perlecan is a potent inducer of bFGF-mediated neovascularization. These results identify perlecan as a major candidate for a bFGF low affinity, accessory receptor and an angiogenic modulator.

Original language	English
Pages (from-to)	1005-1013
Number of pages	9
Journal	Cell
Volume	79
Issue number	6
DOIs	https://doi.org/10.1016/0092-8674(94)90031-0
State	Published - 16 Dec 1994
Externally published	Yes

Bibliographical note

Funding Information:
The corresponding author for this work is A. Y. We thank Dougias Noonan and Israel Vlodavsky for most helpful discussions, Tammy Gray and Nathen Aviezer for critical reading of the manuscript, and Tova Shimon and Rosemarie Flick for their excellent technical assistance, This work was supported in part by grants from the Israel Academy of Science, Israel Cancer Research Fund, Minerva Foundation, USA-Israel Binational Science Foundation, the Nationaal Fonds voor Wetenschappelijk Onderzoek of Belgium (grant 3.0073.91), Leven-slijn-1991-Hart en Bloedvaten (grant 7.0043.91), and the Interuniversity Network for Fundamental Research sponsored by the Belgian government. A. Y. is an incumbent of the Alvin and Gertrude Levine Career Development Chair of Cancer Research.

Funding

The corresponding author for this work is A. Y. We thank Dougias Noonan and Israel Vlodavsky for most helpful discussions, Tammy Gray and Nathen Aviezer for critical reading of the manuscript, and Tova Shimon and Rosemarie Flick for their excellent technical assistance, This work was supported in part by grants from the Israel Academy of Science, Israel Cancer Research Fund, Minerva Foundation, USA-Israel Binational Science Foundation, the Nationaal Fonds voor Wetenschappelijk Onderzoek of Belgium (grant 3.0073.91), Leven-slijn-1991-Hart en Bloedvaten (grant 7.0043.91), and the Interuniversity Network for Fundamental Research sponsored by the Belgian government. A. Y. is an incumbent of the Alvin and Gertrude Levine Career Development Chair of Cancer Research.

Funders	Funder number
Belgian government
Dougias Noonan and Israel Vlodavsky
Leven-slijn-1991-Hart en Bloedvaten	7.0043.91
USA-Israel Binational Science Foundation
Israel Cancer Research Fund
Minerva Foundation
Fonds Wetenschappelijk Onderzoek	3.0073.91

Access to Document

10.1016/0092-8674(94)90031-0

Cite this

@article{61a1a56c3e3445b686593206801462c7,

title = "Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis",

abstract = "A survey of defined species of cell surface and extracellular matrix heparan sulfate proteoglycans (HSPG) was performed in a search for cellular proteoglycans that can promote bFGF receptor binding and biological activity. Of the various affinity-purified HSPGs tested, perlecan, the large basement membrane HSPG, is found to induce high affinity binding of bFGF both to cells deficient in HS and to soluble FGF receptors. Heparin-dependent mitogenic activity of bFGF is strongly augmented by perlecan. Monoclonal antibodies to perlecan extract the receptor binding promoting activity from active HSPG preparations. In a rabbit ear model for in vivo angiogenesis, perlecan is a potent inducer of bFGF-mediated neovascularization. These results identify perlecan as a major candidate for a bFGF low affinity, accessory receptor and an angiogenic modulator.",

author = "David Aviezer and Dalit Hecht and Michal Safran and Magdalena Eisinger and Guido David and Avner Yayon",

note = "Funding Information: The corresponding author for this work is A. Y. We thank Dougias Noonan and Israel Vlodavsky for most helpful discussions, Tammy Gray and Nathen Aviezer for critical reading of the manuscript, and Tova Shimon and Rosemarie Flick for their excellent technical assistance, This work was supported in part by grants from the Israel Academy of Science, Israel Cancer Research Fund, Minerva Foundation, USA-Israel Binational Science Foundation, the Nationaal Fonds voor Wetenschappelijk Onderzoek of Belgium (grant 3.0073.91), Leven-slijn-1991-Hart en Bloedvaten (grant 7.0043.91), and the Interuniversity Network for Fundamental Research sponsored by the Belgian government. A. Y. is an incumbent of the Alvin and Gertrude Levine Career Development Chair of Cancer Research.",

year = "1994",

month = dec,

day = "16",

doi = "10.1016/0092-8674(94)90031-0",

language = "אנגלית",

volume = "79",

pages = "1005--1013",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "6",

}

TY - JOUR

T1 - Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis

AU - Aviezer, David

AU - Hecht, Dalit

AU - Safran, Michal

AU - Eisinger, Magdalena

AU - David, Guido

AU - Yayon, Avner

N1 - Funding Information: The corresponding author for this work is A. Y. We thank Dougias Noonan and Israel Vlodavsky for most helpful discussions, Tammy Gray and Nathen Aviezer for critical reading of the manuscript, and Tova Shimon and Rosemarie Flick for their excellent technical assistance, This work was supported in part by grants from the Israel Academy of Science, Israel Cancer Research Fund, Minerva Foundation, USA-Israel Binational Science Foundation, the Nationaal Fonds voor Wetenschappelijk Onderzoek of Belgium (grant 3.0073.91), Leven-slijn-1991-Hart en Bloedvaten (grant 7.0043.91), and the Interuniversity Network for Fundamental Research sponsored by the Belgian government. A. Y. is an incumbent of the Alvin and Gertrude Levine Career Development Chair of Cancer Research.

PY - 1994/12/16

Y1 - 1994/12/16

N2 - A survey of defined species of cell surface and extracellular matrix heparan sulfate proteoglycans (HSPG) was performed in a search for cellular proteoglycans that can promote bFGF receptor binding and biological activity. Of the various affinity-purified HSPGs tested, perlecan, the large basement membrane HSPG, is found to induce high affinity binding of bFGF both to cells deficient in HS and to soluble FGF receptors. Heparin-dependent mitogenic activity of bFGF is strongly augmented by perlecan. Monoclonal antibodies to perlecan extract the receptor binding promoting activity from active HSPG preparations. In a rabbit ear model for in vivo angiogenesis, perlecan is a potent inducer of bFGF-mediated neovascularization. These results identify perlecan as a major candidate for a bFGF low affinity, accessory receptor and an angiogenic modulator.

AB - A survey of defined species of cell surface and extracellular matrix heparan sulfate proteoglycans (HSPG) was performed in a search for cellular proteoglycans that can promote bFGF receptor binding and biological activity. Of the various affinity-purified HSPGs tested, perlecan, the large basement membrane HSPG, is found to induce high affinity binding of bFGF both to cells deficient in HS and to soluble FGF receptors. Heparin-dependent mitogenic activity of bFGF is strongly augmented by perlecan. Monoclonal antibodies to perlecan extract the receptor binding promoting activity from active HSPG preparations. In a rabbit ear model for in vivo angiogenesis, perlecan is a potent inducer of bFGF-mediated neovascularization. These results identify perlecan as a major candidate for a bFGF low affinity, accessory receptor and an angiogenic modulator.

UR - http://www.scopus.com/inward/record.url?scp=0028579734&partnerID=8YFLogxK

U2 - 10.1016/0092-8674(94)90031-0

DO - 10.1016/0092-8674(94)90031-0

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 7528102

AN - SCOPUS:0028579734

SN - 0092-8674

VL - 79

SP - 1005

EP - 1013

JO - Cell

JF - Cell

IS - 6

ER -

Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis

Abstract

Bibliographical note

Funding

Access to Document

Other files and links

Fingerprint

Cite this